News

Under the agreement Eurogentec will promote Delphi Genetics’s StabyDNA technology for use in GMP manufacturing on an exclusive basis. The financial terms of the agreement were not disclosed.

The confirmatory Phase III trial is a 400-patient, multi-center, double-blind, randomized, placebo-controlled study conducted in 48 centers in North America and Europe. It is designed to confirm the

The approval is based on efficacy results from a multicenter clinical study that included a 12-week randomized, double-blind placebo phase followed by a 40-week open-label phase. Premarin vaginal

INO-8875 is a selective adenosine 1 agonist in Phase I clinical development as a topical agent for the treatment of elevated intraocular pressure associated with primary open angle

The acquisition is expected to add nearly $50 million of annual sales and be accretive to earnings in the first 12 months. Joseph Papa, chairman and CEO of

The randomized, double-blind placebo controlled study will evaluate the safety, tolerability and pharmacokinetics of ascending doses of CH-4051 in healthy male volunteers and is being conducted at Kendle

Based on the results from this study, Lexicon is planning to initiate a Phase II study in patients with carcinoid syndrome. LX1032 will be Lexicon’s third drug candidate

According to the company, the offer expired, as scheduled on November 12, 2008. A total of 41.13 million common shares of CryoCath were validly deposited at the time

The agreement states that Cardio Neo-Genesis (CNG) can fund up to $15 million of the clinical development for the company’s coronary heart disease (CHD) drug candidate. The agreement